MANCHESTER (SALFORD): 164 patients from a tertiary centre, review at 3 and 6 months2,3
MANCHESTER (SALFORD)3 (N=164) |
|
---|---|
Median age (years) | 36 (18–87) |
Males (%) | 59.75 |
Median baseline EASI Score | 23 ± 16 |
Median baseline DLQI Score | 22 ± 10 |
Proportion of patients achieving EASI-50, EASI-75 and EASI-902-4
In Manchester at 6 months, 75% of patients on DUPIXENT achieved a >75% improvement in lesion extent and severity (EASI-75) compared to 62% with DUPIXENT at 3 months2-4
Mean EASI score at baseline and review checkpoints*2
At 6 months, a mean EASI score of 3.43 was achieved by 87 patients on DUPIXENT, compared to a mean EASI score of 24.54 at baseline2
Mean DLQI score at baseline and review checkpoints*2
At 6 months, a mean DLQI score of 4.15 was achieved by 81 patients on DUPIXENT, compared to a mean DLQI score of 20.27 at baseline2
A retrospective review of the electronic records of patents receiving DUPIXENT at the Dermatology Centre part of the Salford Royal Hospital NHS Foundation Trust (N=164). Baseline demographics, EASI and DLQI scores were collected at baseline, 3 and 6 months.2,3
CAFÉ trial design: A 16-week, Phase 3, double-blind, randomised, placebo-controlled trial of adults with moderate-to-severe AD, who are inadequately controlled by, or intolerant of ciclosporin. A total of 325 patients in Europe were randomised into three treatment groups in the 16-week study to receive either DUPIXENT 300 mg + TCS QW, DUPIXENT 300 mg + TCS Q2W (licensed dose) or placebo + TCS. Patients applied moisturisers at least twice daily for the seven days prior to randomisation and throughout the study; stable doses of prescription moisturisers or moisturisers containing additives were permitted if initiated before screening.4
The primary endpoint was the proportion of patients that achieved a 75% or greater improvement in the EASI-75 score at 16 weeks from baseline.4
Secondary endpoints included: measures of the impact of DUPIXENT on the persistent itch caused by the disease, health-related quality of life measures, and symptoms of anxiety and depression. A clinically meaningful improvement in pruritus is defined as a ≥4-point improvement in NRS. A clinically meaningful improvement in quality of life is defined as ≥4-point improvement on a 0–30 scale in DLQI.4
*An EASI score is based on a clinician’s weighted score (0 to 72) of four affected areas grading the physical signs of AD (erythema, oedema/papulation, excoriation, lichenification).5–9
†The DLQI score is based on a 10-item patient questionnaire that assesses six different aspects that may affect quality of life. These aspects are symptoms and feelings, daily activities, leisure, work and school performance, personal relationships, and treatment. Each question is scored from 0 (not at all) to 3 (very much) and then totalled for the final score.5–9
AD, atopic dermatitis; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; RWE, real world evidence.
References